Most Cited Article – A Copeptin as a Predictor Marker for Insulin Resistance Among Women with Polycystic Ovary Syndrome

Author(s):Alaa Ibrahim Ali *Wassan Nori Mohammed Hassan and Sumaya Alrawi

Volume 18, Issue 4, 2022

Published on: 12 January, 2022

Article ID: e081221198670

Pages: 6

DOI: 10.2174/1573404817666211208152049

Abstract

Background: A polycystic ovarian syndrome (PCOS) is a common endocrine syndrome in which women have a wide range of clinical presentations; insulin resistance was linked to its pathogenesis.

Objective: We aimed to investigate the copeptin role as a predictive marker of insulin resistance among PCOS women.

Materials and Methods: In University Hospital, we included 280 women, with 140 of them being healthy controls. 140 out of 280 cases of PCOS subdivided into two groups depending on the insulin resistance; group 1 with homeostasis model assessment for the insulin resistance < 2.5. Group 2 with homeostasis model assessment for the insulin resistance >2.5. The evaluation of body mass index and blood pressure for all besides the blood sampling for estimation of a follicular stimulating hormone, luteinizing hormone, prolactin, estradiol, sex hormone-binding globulin, total testosterone, fasting insulin dehydroepiandrosterone sulfate, C-reactive protein, plasma glucose, free androgen index, and plasma copeptin using the Copeptin-Human EIA Kit besides the transvaginal ultrasound for ovarian assessment.

Results: When compared to other groups, PCOS women with positive insulin resistance >2.5 had a significantly higher plasma copeptin level. The ROC curve calculated a 1.94 pmol/L; plasma copeptin cutoff value for detecting the insulin resistance in PCOS with 88 % sensitivity value and 36 % specificity, AUC was 0.88.

Conclusion: The significant positive relationship between serum copeptin and insulin resistance with high sensitivity implies its usefulness as a marker of insulin resistance among PCOS patients with a high prediction of its complication. Read now: https://bit.ly/3eEpGSZ

Call for Papers | Current Pharmaceutical Design

Special Thematic Issues | Forthcoming Issues

Journal: Current Pharmaceutical Design

 

Guest Editor(s): Celestino Sardu
Tentative Publication Date: January, 2020

 

“Metabolic Syndrome impact on molecular, and cellular functions in patients affected by heart failure: therapeutic, diagnostic and clinical applications”

Ametabolic Syndrome.jpg

 

In this Special Issue we would try to bring the two major diseases together by focusing on common molecular pathways, mechanisms and subsequently on clinical outcomes. We may speculate that, the identification of mechanisms underlying the pathophysiology of MS and its CV complications may represent an area of significant research efforts, attracting scientists and clinicians from a diverse range of fields including biochemistry, pharmacology, internal medicine, cardiology and geriatrics among several others.Our Special Issue hypothesis is that, the final goal in the near future will be to find treatments better tailored to MS patients with HF using a personalized–medicine approach. Therefore, here we invite investigators to submit to this Special Issue both original research articles, clinical trials and reviews having the purpose to address novel diagnostic tools or new therapeutic treatments for MS and HF. For more details please visit: https://benthamscience.com/journal-files/special-issue-details/CPD-SII20181228-01.pdf

 

To submit your paper, email at: hermain@benthamscience.net and CC: faizan@benthamscience.net

Highlighted Article – The Role of Diet in Patients with Metabolic Syndrome – Current Medicinal Chemistry

Prof. Nahum Mendez-Sanchez.jpg

To access this article, please visit: http://www.eurekaselect.com/152533

Most Accessed Articles – “Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome”

Journal: Medicinal Chemistry

mcAbstract: Metabolic syndrome is a disorder described by reduced insulin sensitivity, overweight, hyperlipidaemia, high blood pressure and myocardial disorders, mainly due to high fat diet and lack of physical activity. The peroxisome proliferator activated receptors (PPARs) are type II nuclear hormone receptors that regulate a number of processes in living systems, such as metabolism of carbohydrates and fatty acids, growth and differentiation of cell, and inflammatory reactions. Alpha, gamma and delta are the three distinct isoforms of PPAR. The stimulation of PPARδ alters body’s energy fuel preference from glucose to fat. The PPARδ isoform is expressed ubiquitously in all tissues, especially in those tissues which involved in metabolism of lipids like adipose tissue, liver, kidney, and muscle. Currently, PPARδ is an emerging therapeutic target for the pharmacological therapy of disorders associated with metabolic syndrome. Several PPARδ selective agonists had been reported in last ten years, many of them had been advanced into the late phase of clinical trials such as Endurobol (GW501516). However, no PPARδ agonists are yet approved for human use. The present work had been planned to cover wide variety of PPARδ agonists reported till now along with their potential role to tackle various metabolic disorders. The present review has been planned to focus mainly the most popular PPARδ agonists.

Read more here: http://benthamscience.com/journals/medicinal-chemistry/volume/12/issue/1/page/3/

Articles by disease – The Metabolic Syndrome and Chronic Liver Disease

Abstract:

The prevalence of the metabolic syndrome (MetS), a cluster of cardiovascular risk factors associated with obesity and insulin resistance, is dramatically increasing in Western and developing countries. This disorder is not only associated with a higher risk of appearance of type 2 diabetes and cardiovascular events, but impacts on the liver in different ways. Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of MetS, and is characterized by triglyceride accumulation and a variable degree of hepatic injury, inflammation, and repair. In the presence of significant hepatocellular injury and inflammation, the picture is defined ‘nonalcoholic steatohepatitis’ (NASH), that has the potential to progress to advanced fibrosis and cirrhosis. Diagnosis of NASH is based on a liver biopsy, and active search for noninvasive tests is ongoing.

– See more at: http://www.eurekaselect.com/node/118614/article#sthash.V6SPy9yJ.dpuf

Does Metabolic Syndrome or its Individual Components Affect Pain and Function in Knee Osteoarthritis Women?

Author(s): Fatima E. Abourazzak, Sofia Talbi, Faiza Lazrak, Hamida Azzouzi, Nassia Aradoini, Salia Keita, Mourad Errasfa and Taoufik Harzy.

Abstract:

Background: Current studies and research support the role of metabolic syndrome (MetS) in knee osteoarthritis (OA). However, few studies have focused on its impact on knee OA parameters. The aim of this study was to investigate if metabolic syndrome or its individual components affect the intensity of pain, functional disability, and radiographic severity in knee osteoarthritis women.Materials and Methods: We conducted a cross sectional study including confirmed radiographic knee osteoarthritis according to Kellgren and Lawrence scale, with and without metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III criteria. The two groups were compared for pain Visual Analogue Scale (VAS), Lequesne index, Womac function, and radiological grade after adjusting for significant covariates. Multiple regression analysis was used to identify the independent effects of each specific component for metabolic syndrome on knee osteoarthritis parameters.

Results: One hundred thirty women were included. The mean age was 56.68 ±8.07 [34-75] years, and the mean BMI was 32.54±2.92 [23-37] kg/m2. The prevalence of metabolic syndrome was 48.5%. Women with and without metabolic syndrome had similar knee osteoarthritis parameters. However, accumulation of MetS components was associated with higher level of pain (OR = 3.7, CI = [1.5-5.9], p=0.001), independently of age and BMI. Multiple regression analyses showed, after adjusting for all covariates, that hyperglycemia had a positive impact on pain (p=0.009), waist circumference was positively associated with Lequesne index (p=0.04), high triglycerides level was significantly associated with increased pain (p=0.04) and higher Lequesne score (p=0.05), and Systolic blood pressure was positively correlated with Lequesne index (p=0.01).

Conclusion: In addition to weight reduction, appropriate treatment of metabolic syndrome needs to become an important management strategy for knee pain and functional impairment.

Current Rheumatology Reviews, 11(1): 8-14.

Download the article from here: http://benthamscience.com/journals/current-rheumatology-reviews/volume/11/issue/1/page/8/

Open Access Plus ::: Recent Patents on Anti-Cancer Drug Discovery

Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Zsuzsanna Suba

Abstract: The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.

View Abstract Download Free

 

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Sarah Shirley, Alexandre Morizot and Olivier Micheau

Abstract: Literary data suggest apparently ambiguous interaction between menopausal status and obesity-associated breast cancer risk based on the principle of the carcinogenic capacity of estrogen. Before menopause, breast cancer incidence is relatively low and adiposity is erroneously regarded as a protective factor against this tumor conferred by the obesity associated defective estrogen-synthesis. By contrast, in postmenopausal cases, obesity presents a strong risk factor for breast cancer being mistakenly attributed to the presumed excessive estrogen-production of their adipose-tissue mass. Obesity is associated with dysmetabolism and endangers the healthy equilibrium of sexual hormone-production and regular menstrual cycles in women, which are the prerequisites not only for reproductive capacity but also for somatic health…

View Abstract Download Free

%d bloggers like this: